Compare evidence.
Keep the context.

Insufficient data in the current dataset

• Long-term benefits and risks in populations broader than those enrolled in the trials
• Final cardiovascular and kidney outcomes from ongoing outcomes programmes
• The indications, labelling, contraindications and conditions regulators may specify if approval is granted in the future
• The quality and actual composition of products sold outside clinical trials

• human pharmacokinetics, bioavailability and target engagement
• safe exposure range and short- or long-term adverse effects in humans
• whether mouse endurance and metabolic findings translate to people
• comparability between published research material and products offered online
• current product-specific status in Thailand, the United States, European Union and United Kingdom
• case-specific anti-doping classification and analytical thresholds

• Tesofensine ≠ GLP-1 ≠ Tesomet; favorable non-binding opinion ≠ marketing authorisation

• Major studies were funded by Eli Lilly, and several authors were affiliated with the company. Populations, durations and comparator groups differed. Some Phase 3 results in 2026 were still reported as topline manufacturer statements rather than peer-reviewed articles. Cross-study comparisons with semaglutide or tirzepatide are not head-to-head evidence.

• The core efficacy literature consists of cell and mouse studies from a limited research lineage. Human-derived cell work does not establish exposure, efficacy or safety in a person. No verified clinical administration dataset means an evidence grade above E is not justified. Later work on SLU-PP-915 is about a different molecule and cannot be transferred to SLU-PP-332.

• Saniona annual report 2025, published 2026 · developer-reported regulatory context
• Phase II obesity RCT · PMID 18950853

• https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
• https://www.gov.uk/government/news/mhra-smashes-majorillicitweight-loss-medicine-production-facility-in-record-seizure
• https://cms.mhra.gov.uk/pip/mhra-102112-pip01-25
• https://www.ema.europa.eu/en/documents/pip-decision/p-0336-2024-ema-decision-13-september-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-retatrutide-emea-003258-pip02-23_en.pdf
• https://pubmed.ncbi.nlm.nih.gov/37366315/
• https://pubmed.ncbi.nlm.nih.gov/37385280/
• https://pubmed.ncbi.nlm.nih.gov/42250575/
• https://clinicaltrials.gov/study/NCT05929066
• https://clinicaltrials.gov/study/NCT05929079
• https://clinicaltrials.gov/study/NCT05882045
• https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional
• https://investor.lilly.com/news-releases/news-release-details/lilly-reports-second-quarter-2026-financial-results-raises-full

• https://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx
• https://www.accessdata.fda.gov/scripts/cder/daf/
• https://clinicaltrials.gov/search?term=%22SLU-PP-332%22
• https://www.ema.europa.eu/en/medicines/download-medicine-data
• https://pubmed.ncbi.nlm.nih.gov/36988910/
• https://pubmed.ncbi.nlm.nih.gov/37739806/
• https://pubmed.ncbi.nlm.nih.gov/40692696/
• https://pubmed.ncbi.nlm.nih.gov/41688415/
• https://pubmed.ncbi.nlm.nih.gov/41421047/
• https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list
• https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
• https://products.mhra.gov.uk/

Complete evidence profile (Thai)

Complete evidence profile (Thai)

Complete evidence profile (Thai)